skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

About Michael

UK

+9 year(s) experience

Michael Haydock | Pharma Intelligence
Director Michael Haydock oversees content production for cardiovascular and metabolic diseases as well as infectious disease and vaccine indications. In his role, Michael provides analysis and strategic recommendations on various disease markets through comparative assessment of marketed and pipeline products and patient-based forecasting.
His specialities include hepatitis B, hepatitis C, HIV, influenza, dengue, pneumococcal vaccines and meningococcal vaccines. In addition to producing analyses on various antiviral and vaccine indications, Michael has designed several primary research surveys, and is currently focused on refining data inputs and forecasting methodology. His greatest achievement is the development of an interactive, patient-based 10-year forecast for the early-phase RSV vaccines landscape – a particularly challenging task given the lack of currently approved vaccines.

He joined Informa as an analyst in 2012, having achieved a first-class degree in Natural Sciences (Immunology and Virology) from the University of Cambridge.

Specialties

  • Infectious Diseases
  • Cardiovascular
  • Metabolic
  • Vaccines

Michael writes For

Analyst Articles

Articles by Michael

  • Biomedtracker, Datamonitor Healthcare

    2020 Early Outlook Webinar

    Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.

    Topic FDA

    Full video

  • Datamonitor Healthcare, Biomedtracker

    Q1 Outlook Webinar: Key Catalysts and their Impact on Pharma Markets

    Find out which market-moving events and catalysts to watch for during the Q1 Outlook Webinar - Key catalysts and their impact on pharma markets.

    Topic Drug approval Drug development landscape Drug review

    Full video

  • Datamonitor Healthcare

    HIV Market Growth webinar

    Mr. Haydock & Mr. Haas used the exclusive information within Datamonitor Healthcare and Biomedtracker to present a view of the market for HIV drugs. Informa Pharma Intelligence forecasts HIV sales revenues to increase in the US and five major EU markets to a peak of $22.7bn in 2024 before generic erosion triggers a market decline.

    Full video

  • Datamonitor Healthcare

    Ensure your successful entrance into the Hepatitis B market

    Ensure your successful entrance into the Hepatitis B market

    Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.

    Topic Hepatitis B Hepatitis

    View infographic

  • Datamonitor Healthcare

    EASL 2014

    EASL 2014

    This white paper from Datamonitor Healthcare identifies and discusses key highlights from the annual meeting of the European Association for the Study of the Liver (EASL), which took place in London, UK, from 9 to 13 April 2014.

    View white paper